Vascular benefits of angiotensin receptor blockers

Bibliography

• RAKUGI H, KIM DK, KRIEGER JE, WANG DS, DZAU VJ, PRATT RE: Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J. Clin. Invest. (1994) 93(1):339-346.
   PubMed Web of Science ®Google Scholar
• DIET F, PRATT RE, BERRY GJ, MOMOSE N, GIBBONS GH, DZAU VJ: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation (1996) 94(11):2756-2767.
   PubMed Web of Science ®Google Scholar
• SCHIEFFER B, SCHIEFFER E, HILFIKER-KLEINER D et al.: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation (2000) 101(12):1372-1378.
   PubMed Web of Science ®Google Scholar
• NICKENIG G, SACHINIDIS A, MICHAELSEN F, BOHM M, SEEWALD S, VETTER H: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation (1997) 95(2):473-478.
   PubMed Web of Science ®Google Scholar
• NICKENIG G, BAUMER AT, TEMUR Y, KEBBEN D, JOCKENHOVEL F, BOHM M: Statinsensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation (1999) 100(21):2131-2134.
   PubMed Web of Science ®Google Scholar
• JOHN S, DELLES C, KLINGBEIL AU, JACOBI J, SCHLAICH MP, SCHMIEDER RE: Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. J. Hypertens. (1999) 17(12 Part 2):1933-1939.
   PubMed Web of Science ®Google Scholar
• VAN DER HARST P, WAGENAAR LJ, BUIKEMA H et al.: Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am. J. Cardiol. (2005) 96(10):1361-1364.
   PubMed Web of Science ®Google Scholar
• WEISS D, KOOLS JJ, TAYLOR WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation (2001) 103(3):448-454.
   PubMed Web of Science ®Google Scholar
• GRAFE M, AUCH-SCHWELK W, ZAKRZEWICZ A et al.: Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ. Res. (1997) 81(5):804-811.
   PubMed Web of Science ®Google Scholar
• PASTORE L, TESSITORE A, MARTINOTTI S et al.: Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation (1999) 100(15):1646-1652.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-PRESA M, BUSTOS C, ORTEGO M et al.: Angiotensin-converting enzyme inhibition prevents arterial NF-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation (1997) 95(6):1532-1541.
   PubMed Web of Science ®Google Scholar
• TUMMALA PE, CHEN XL, SUNDELL CL et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation (1999) 100(11):1223-1229.
   PubMed Web of Science ®Google Scholar
• TAYEH MA, SCICLI AG: Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proc. Assoc. Am. Physicians (1998) 110(5):412-421.
   PubMedGoogle Scholar
• MULLER DN, DECHEND R, MERVAALA EM et al.: NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension (2000) 35(1 Part 2):193-201.
   PubMed Web of Science ®Google Scholar
• CHEN XL, TUMMALA PE, OLBRYCH MT, ALEXANDER RW, MEDFORD RM: Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. (1998) 83(9):952-959.
   PubMed Web of Science ®Google Scholar
• ITOH H, MUKOYAMA M, PRATT RE, GIBBONS GH, DZAU VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Invest. (1993) 91(5):2268-2274.
   PubMed Web of Science ®Google Scholar
• DAUGHERTY A, MANNING MW, CASSIS LA: Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br. J. Pharmacol. (2001) 134(4):865-870.
   PubMed Web of Science ®Google Scholar
• NAVALKAR S, PARTHASARATHY S, SANTANAM N, KHAN BV: Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J. Am. Coll. Cardiol. (2001) 37(2):440-444.
   PubMed Web of Science ®Google Scholar
• KHAN BV, NAVALKAR S, KHAN QA, RAHMAN ST, PARTHASARATHY S: Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J. Am. Coll. Cardiol. (2001) 38(6):1662-1667.
   PubMed Web of Science ®Google Scholar
• DOL F, MARTIN G, STAELS B et al.: Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. (2001) 38(3):395-405.
   PubMed Web of Science ®Google Scholar
• CHEN H, LI D, MEHTA JL: Modulation of matrix metalloproteinase-1, its tissue inhibitor, and NF-κB by losartan in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. (2002) 39(3):332-339.
   PubMed Web of Science ®Google Scholar
• RAHMAN ST, LAUTEN WB, KHAN QA, NAVALKAR S, PARTHASARATHY S, KHAN BV: Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am. J. Cardiol. (2002) 89(6):686-690.
   PubMed Web of Science ®Google Scholar
• BENETOS A, GAUTIER S, LAFLECHE A et al.: Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans. J. Vasc. Res. (2000) 37(1):8-15.
   PubMed Web of Science ®Google Scholar
• KOHNO M, OHMORI K, NOZAKI S et al.: Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertens. Res. (2000) 23(6):677-681.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, PARK JB, PU Q: Effect of crossing over hypertensive patients from a bblocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J. Hypertens. (2002) 20(1):71-78.
   PubMed Web of Science ®Google Scholar
• SIHM I, SCHROEDER AP, AALKJAER C et al.: Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Am. J. Cardiol. (1995) 76:E38-E40.
   PubMedGoogle Scholar
• RIZZONI D, PORTERI E, PICCOLI A et al.: Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension (1998) 32(2):305-310.
   PubMed Web of Science ®Google Scholar
• THYBO NK, STEPHENS N, COOPER A, AALKJAER C, HEAGERTY AM, MULVANY MJ: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension (1995) 25(4 Part 1):474-481.
   PubMed Web of Science ®Google Scholar
• SHARIFI AM, LI JS, ENDEMANN D, SCHIFFRIN EL: Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. (1998) 16:457-466.
   PubMed Web of Science ®Google Scholar
• SCHWEMMER M, SOMMER O, BASSENGE E: Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc. Drugs Ther. (2001) 15(4):301-307.
   PubMed Web of Science ®Google Scholar
• SALOMAA V, STINSON V, KARK JD, FOLSOM AR, DAVIS CE, WU KK: Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Atherosclerosis risk in communities study. Circulation (1995) 91(2):284-290.
   PubMed Web of Science ®Google Scholar
• OUBINA MP, DE LAS HN, VAZQUEZ-PEREZ S et al.: Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J. Hypertens. (2002) 20(2):303-310.
   PubMed Web of Science ®Google Scholar
• SOLA S, MIR MQ, CHEEMA FA et al.: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation (2005) 111(3):343-348.
   PubMed Web of Science ®Google Scholar
• GOODFIELD NE, NEWBY DE, LUDLAM CA, FLAPAN AD: Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation (1999) 99(23):2983-2985.
   PubMed Web of Science ®Google Scholar
• BROWN NJ, AGIRBASLI M, VAUGHAN DE: Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension (1999) 34(2):285-290.
   PubMed Web of Science ®Google Scholar
• SELJEFLOT I, MOAN A, KJELDSEN S, SANDVIK E, ARNESEN H: Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension (1996) 27(6):1299-1304.
   PubMed Web of Science ®Google Scholar
• KUBO A, FUKUDA N, SOMA M, IZUMI Y, KANMATSUSE K: Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1996) 27(1):58-63.
   PubMed Web of Science ®Google Scholar
• SONG K, SHIOTA N, TAKAI S et al.: Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis (1998) 138(1):171-182.
   PubMed Web of Science ®Google Scholar
• HOPE S, BRECHER P, CHOBANIAN AV: Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am. J. Hypertens. (1999) 12(1 Part 1):28-34.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI M, SAKONJO H, TAKAI S: Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br. J. Pharmacol. (1999) 128(3):523-529.
   PubMed Web of Science ®Google Scholar
• CANDIDO R, ALLEN TJ, LASSILA M et al.: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation (2004) 109(12):1536-1542.
   PubMed Web of Science ®Google Scholar
• TAKAI S, JIN D, SAKAGUCHI M et al.: Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens. Res. (2004) 27(7):517-522.
   PubMed Web of Science ®Google Scholar
• VERMA S, STRAUSS M: Angiotensin receptor blockers and myocardial infarction. Br. Med. J. (2004) 329(7477):1248-1249.
   PubMed Web of Science ®Google Scholar
• CHEUNG BM, CHEUNG GT, LAUDER IJ, LAU CP, KUMANA CR: Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J. Hum. Hypertens. (2006) 20(1):37-43.
   PubMed Web of Science ®Google Scholar
• LEVY BI: Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation (2004) 109(1):8-13.
   PubMed Web of Science ®Google Scholar
• WOLF G, ZIYADEH FN, THAISS F et al.: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J. Clin. Invest. (1997) 100:1047-1058.
   PubMed Web of Science ®Google Scholar
• KIM MP, ZHOU M, WAHL LM: Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J. Leukoc. Biol. (2005) 78:195-201.
   PubMed Web of Science ®Google Scholar
• VERDECCHIA P, ANGELI F, GATTOBIGIO R, REBOLDI GP: Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur. Heart J. (2005) 26(22):2381-2386.
   PubMed Web of Science ®Google Scholar
• MCDONALD MA, SIMPSON SH, EZEKOWITZ JA, GYENES G, TSUYUKI RT: Angiotensin receptor blockers and risk of myocardial infarction: systematic review. Br. Med. J. (2005) 331(7521):873.
   PubMedGoogle Scholar
• VOLPE M, MANCIA G, TRIMARCO B: Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J. Hypertens. (2005) 23(12):2113-2118.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ LA, SPENCER DD, KACZMAR T Jr: Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke (1986) 17(1):82-85.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ LA, CARIDE VJ, STROMBERG C, NAVERI L, WICKE JD: Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J. Cardiovasc. Pharmacol. (1994) 24(6):937-940.
   PubMed Web of Science ®Google Scholar
• DALMAY F, MAZOUZ H, ALLARD J, PESTEIL F, ACHARD JM, FOURNIER A: Non-AT1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J. Renin Angiotensin Aldosterone Syst. (2001) 2(2):103-106.
   PubMed Web of Science ®Google Scholar
• NISHIMURA Y, ITO T, HOE K, SAAVEDRA JM: Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT1 receptors. Brain Res. (2000) 871(1):29-38.
   PubMed Web of Science ®Google Scholar
• ITO T, YAMAKAWA H, BREGONZIO C, TERRON JA, FALCON-NERI A, SAAVEDRA JM: Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke (2002) 33(9):2297-2303.
   PubMed Web of Science ®Google Scholar
• DAI WJ, FUNK A, HERDEGEN T, UNGER T, CULMAN J: Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke (1999) 30(11):2391-2398.
   PubMed Web of Science ®Google Scholar
• SOBEY CG: Bradykinin B2 receptor antagonism: a new direction for acute stroke therapy? Br. J. Pharmacol. (2003) 139(8):1369-1371.
   PubMed Web of Science ®Google Scholar
• DING-ZHOU L, MARGAILL I, PALMIER B, PRUNEAU D, PLOTKINE M, MARCHAND-VERRECCHIA C: LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia. Br. J. Pharmacol. (2003) 139(8):1539-1547.
   PubMed Web of Science ®Google Scholar
• TAKADA J, IBAYASHI S, NAGAO T, OOBOSHI H, KITAZONO T, FUJISHIMA M: Bradykinin mediates the acute effect of an angiotensin-converting enzyme inhibitor on cerebral autoregulation in rats. Stroke (2001) 32(5):1216-1219.
   PubMed Web of Science ®Google Scholar
• GOHLKE P, KUWER I, SCHNELL A, AMANN K, MALL G, UNGER T: Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension (1997) 29(1 Part 2):478-482.
   PubMed Web of Science ®Google Scholar
• MAHMOUDIAN M, MEHRPOUR M, BENAISSA F, SIADATPOUR Z: A preliminary report on the application of noscapine in the treatment of stroke. Eur. J. Clin. Pharmacol. (2003)59:579-581.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995-1003.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, DAHLOF B, KJELDSEN SE et al.: Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. (2003) 139(3):169-177.
   PubMed Web of Science ®Google Scholar
• LITHELL H, HANSSON L, SKOOG I et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. (2003) 21(5):875-886.
   PubMed Web of Science ®Google Scholar
• SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke (2003) 34(7):1699-1703.
   PubMed Web of Science ®Google Scholar
• SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: MOSES study group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36(6):1218-1226.
   PubMed Web of Science ®Google Scholar
• PRESCOTT MF, WEBB RL, REIDY MA: Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am. J. Pathol. (1991) 139(6):1291-1296.
   PubMed Web of Science ®Google Scholar
• OSTERRIEDER W, MULLER RK, POWELL JS, CLOZEL JP, HEFTI F, BAUMGARTNER HR: Role of angiotensin II in injury-induced neointima formation in rats. Hypertension (1991) 18(Suppl. 4):II60-II64.
   Google Scholar
• RUMBLE JR, KOMERS R, COOPER ME: Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J. Hypertens. (1996) 14(5):601-607.
   PubMed Web of Science ®Google Scholar
• TAGUCHI J, ABE J, OKAZAKI H et al.: Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application. Biochem. Biophys. Res. Commun. (1993) 196(2):969-974.
   PubMed Web of Science ®Google Scholar
• KUBO A, FUKUDA N, SOMA M, IZUMI Y, KANMATSUSE K: Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1996) 27(1):58-63.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, DELISEE C, DOL F et al.: Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur. J. Pharmacol. (1994) 251(2-3):143-150.
   PubMed Web of Science ®Google Scholar
• VARTY K, ALLEN KE, JONES L, SAYERS RD, BELL PR, LONDON NJ: Influence of losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein. Br. J. Surg. (1994) 81(6):819-822.
   PubMed Web of Science ®Google Scholar
• HUCKLE WR, DRAG MD, ACKER WR et al.: Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation (1996) 93(5):1009-1019.
   PubMed Web of Science ®Google Scholar
• HUBER KC, SCHWARTZ RS, EDWARDS WD et al.: Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am. Heart J. (1993) 125(3):695-701.
   PubMed Web of Science ®Google Scholar
• PETERS S, GOTTING B, TRUMMEL M, RUST H, BRATTSTROM A: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J. Invasive Cardiol. (2001) 13(2):93-97.
   PubMed Web of Science ®Google Scholar
• YOSHIDA O, HIRAYAMA H, NANASATO M, WATANABE T, MUROHARA T: The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am. Heart J. (2005) 149(1):e2.
   PubMedGoogle Scholar
• RADKE PW, FIGULLA HR, DREXLER H et al.: AACHEN trial investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am. Heart. J. (2006) 152(4):761.e1-e6.
   PubMedGoogle Scholar
• DEMERS C, MCMURRAY JJ, SWEDBERG K et al.: CHARM investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA (2005) 294(14):1794-1798.
   PubMed Web of Science ®Google Scholar